China's drug regulator approved Chongqing Taiji Industry's (SHA:600129) supplementary drug application for its digoxin injection, according to a Saturday filing with the Shanghai bourse.
The injection helps treat mild to moderate heart failure in adults and increases cardiac force in children with heart failure, the filing said.
Real estate developer Kalpataru (NSE:KALPATARU, BOM:544423) has secured a cluster redevelopment project comprising five adjacent residential societies in the Kandivili area of Mumbai, India, according to a Monday filing to the Indian stock exchanges.The project spans 2.8 acres of land with a free sale potential of 0.37 million square feet (msf) carpet area and an estimated gross development value of around 12.5 billion rupees.The company has already delivered six development projects in the Kandivili area.
Hainan Huluwa Pharmaceutical's (SHA:605199) zoledronic acid concentrate for injection obtained a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's shares jumped 3% at the close of Monday's trade.The drug is used in combination with standard antitumor therapy for the treatment of skeletal complications in patients with bone metastases from solid tumors and multiple myeloma.
Shibaura Machine's (TYO:6104) profit attributable to owners of the parent plunged 92% to 1.03 billion yen for the fiscal year 2025 from 12.6 billion yen a year earlier.The machinery manufacturer's basic earnings per share declined to 43.51 yen from 529.56 yen a year ago, according to a Tokyo bourse filing on Monday.Net sales dropped 21% to 132.8 billion yen from 168.2 billion yen in the prior year.It declared a final dividend of 70 yen per share, payable from June 16.For the fiscal year 2026, the company expects attributable profit of 2 billion yen, basic EPS of 84.58 yen, and net sales/revenue of 137 billion yen.Shibaura Machine plans to pay interim and year-end dividends of 70 yen per share, each, for the year, which is the same as the amount declared in the year-ago period.